Dr. Richard Hopkins is an experienced bio-pharmaceutical executive with over 20 years in corporate leadership roles with public biotechnology companies. He has an established track record in drug development of novel therapies with a particular focus in oncology and medicinal cannabis, corporate strategy and financing, business development and intellectual property.
Dr. Hopkins recently served as the Managing Director ex-USA for Zelira Therapeutics; a leading global company focused on clinical validation of medical cannabis as a treatment for Autism. Prior to this, Dr Hopkins served as Chief Executive Officer at PharmAust where he oversaw clinical development of a novel cancer therapy for humans and dogs. He was also a co-founder of Phylogica, where, in addition to the CEO role, he served in variety of positions, including Chief Scientific Officer, and Chief Operating Officer where he led a team of over 25 scientists.
During his career, Dr. Hopkins and managed and overseen strategic alliances and licensing deals with multiple global pharmaceutical partners including J&J, Pfizer, Roche, Genentech, AstraZeneca/Medimmune.
Dr. Hopkins currently serves as Executive Chairman of MyoPharm Pty Ltd, a Non executive Director of Rex Ortho Pty Ltd, a medical device company developing a novel devices for surgical fixation as well as serving on the Board of Directors of BlinkLab.
Dr. Hopkins is an author on over 30 peer-reviewed publications and is an inventor on 15 patents and patent applications.